Cancer prevention trial of a synergistic mixture of green tea concentrate plus capsicum (capsol-t) in a random population of subjects ages 40-84

Clinical Proteomics

Volumn 11, Issue 1, 2014, Pages

  Hanau, Claudia ^a   Morré, D James ^b   Morré, Dorothy M ^b  

^a HANAU Health Services Inc   (United States)

^b Purdue Research Park   (United States)

Author keywords

Cancer; Capsol t ; Curative prevention ; Early detection; Early intervention; Green tea concentrate; Oncoblot tissue of origin cancer test; Prevention trial

Indexed keywords

ANTINEOPLASTIC AGENT; CAPSOL T; ENOX2 PROTEIN; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD LEVEL; CANCER DIAGNOSIS; CANCER PREVENTION; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE MARKER; DRUG EFFICACY; DRUG MIXTURE; DRUG RESPONSE; DRUG TARGETING; EVENING DOSAGE; FEMALE; HUMAN; HUMAN TISSUE; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; PEPPER; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; TEA; TREATMENT DURATION; VERY ELDERLY;

EID: 84903716032     PISSN: 15426416     EISSN: 15590275     Source Type: Journal    
DOI: 10.1186/1559-0275-11-2     Document Type: Article

References (43)

1. American Cancer Society: Facts and Figures 2013. Atlanta: American Cancer Society; 2013.
2. Siegel R, Naidhadham D, Jemal A: Cancer statistics 2012. CA. A Cancer J Clin 2012, 62(1):10-29.
3. ISEER. In Cancer Statistics Review, 1975-2010. Edited by Howlader N, Noone AM, Krapcho M, Garshel J, Neyman N, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Lewis DR, Chen HS, Feuer EJ, in KA C. Bethesda, MD: Nat Cancer Ins; 2013. http://seer.cancer.gov/csr/1975-2010/. Based on November 2012 SEER data submission, posted to the SEER web site.
4. Coghlin C, Murray GI: Current and emerging concepts in tumor metastasis. J Pathol 2010, 222(1):1-35.
5. Morré DJ, Morré DM: Early detection: An opportunity for cancer prevention through early intervention. In Cancer Prevention. Edited by Georgakilas AG. Rijeka: In Tech; 2012:389-402.
6. Chueh PJ, Kim C, Cho N, Morré DM, Morré DJ: Molecular cloning and characterization of a tumor-associated, growth-related, and timekeeping hydroquinone (NADH) oxidase (tNOX) of the HeLa cell surface. Biochemistry 2002, 41(11):3732-3741. (Pubitemid 34224687)
7. Morré DJ, Morré DM: ECTO-NOX Proteins. New York: Springer; 2013:507.
8. Cho N, Chueh PJ, Kim C, Caldwell S, Morré DM, Morré DJ: Monoclonal antibody to a cancer- specific and drug-responsive hydroquinone (NADH) oxidase from the sera of cancer patients. Cancer Immunol Immunother 2002, 51(3):121-129. (Pubitemid 34298107)
9. Morré DJ, Morré DM: Cell surface NADH oxidases (ECTO-NOX proteins) with roles in cancer, cellular time-keeping, growth, aging and neurodegenerative diseases. Free Radic Res 2003, 37(18):795-808. (Pubitemid 36939596)
10. Tang X, Tian Z, Chueh PJ, Chen S, Morré DM, Morré DJ: Alternative splicing as the basis for specific localization of tNOX, a unique hydroquionone (NADH) oxidase, to the cancer cell surface. Biochemistry 2007, 46(43):12337-12346. (Pubitemid 350022388)
11. Tang X, Morré DJ, Morré DM: Antisense experiments demonstrate an exon 4 minus splice variant mRNA as the basis for expression of tNOX, a cancer-specific cell surface protein. Oncol Res 2008, 16(12):557-567. (Pubitemid 351344778)
12. Davies SL, Bozzo J: Spotlight on tNOX: A tumor-selective target for cancer therapies. Drug News Prospect 2006, 19(4):223-225.
13. Del Principe D, Avigalo L, Savini I, Catani MV: Trans-plasma membrane electron transport in mammals: functional significance in health and disease. Antioxid Redox Signal 2011, 14(11):2289-2318.
14. Hostetler B, Weston N, Kim C, Morré DM, Morré DJ: Cancer site-specific isoforms of ENOX2 (tNOX), a cancer-specific cell surface oxidase. Clin Proteomics 2009, 5:46-51.
15. Pisters KM, Newman RA, Coldman B, Shin DM, Khuri FR, Hong WK, Glisson BS, Lee JS: A Phase 1 trial of oral green tea extract in adult patients with solid tumors. J Clin Oncol 2001, 19(6):1830-1838. (Pubitemid 32230886)
16. Jatoi A, Ellison N, Burch PA, Sloan JA, Dakhil SR, Novotny P, Tan W, Fitch TR, Rowland KM, Young CY, Flynn PJ: A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer 2003, 97(6):1442-1446. (Pubitemid 36297774)
17. Yagiz K, Morré DJ, Morré DM: Transgenic mouse expressing the cancerspecific tNOX protein has an enhanced growth and acquired drugresponse phenotype. J Nutr Biochem 2006, 17(11):750-759. (Pubitemid 44557048)
18. Golden EB, Lam PY, Kardosh A, Faffney KJ, Cadenas E, Louie SG, Patasis NA, Chen TC, Schontal AH: Green tea polyphenols block the anticancer effects bortezomib and other boronic acid-based proteasome inhibitors. Blood 2009, 113(23):5927-5937.
19. Weinberg RA: The Biology of Cancer, Garland Science, New York. (Fig. 11.1, Courtesy of WK Hong compiled from SEER Cancer Statistics Review). New York: Garland Science; 1996:796.
20. Jin XP, Peng JB, Pang H, Zhu YN, Fei J, Gup LH: A mRNA molecule encoding truncated excitatory amino acid carrier 1 (EAAC1) protein (EAAC2) is transcribed from an independent promoter but not as an alternative splicing event. Cell Res 2002, 12(3-4):257-262. (Pubitemid 135707528)
21. Michaelson J, Salija S, Moore B, Weber G, Halpern E, Garland A, Kopans DB, Hughes K: Estimates of the sizes at which breast cancers become detectable on mammograms and clinical grounds. J Women's Imaging 2003, 5(1):3-10. (Pubitemid 36758063)
22. Morré DJ, Bridge A, Wu LY, Morré DM: Preferential inhibition by (-)-epigallocatechin-3-gallate of the cell surface NADH oxidase and growth of transformed cells in culture. Biochem Pharmacol 2000, 60(7):937-946.
23. Morré DJ, Chueh P-J, Morré DM: Capsaicin inhibits preferentially the NADH oxidase and growth of transformed cells in culture. Proc Natl Acad Sci USA 1995, 92(6):1831-1835.
24. Morré DJ, Morré DM, Sun H, Cooper R, Chang J, Janle EM: Tea catechin synergies in inhibition of cancer cell proliferation and of a cancerspecific cell surface oxidase (ECTO-NOX). Pharmacol Toxicol 2003, 92(5):234-241. (Pubitemid 36513219)
25. Morré DJ, Morré DM: Synergistic Capsicum-tea mixtures with anticancer activity. J Pharm Pharm 2003, 55(7):987-994. (Pubitemid 36916689)
26. Janle E, Morré DM, Morré DJ, Zhou Q, Chang H, Zhu Y: Pharmacokinetics of green tea catechins in extract and sustained-release preparations. J Dietary Suppl 2008, 5(3):248-263.
27. Fujiki H: Two stages of cancer prevention with green tea. J Cancer Res Clin Oncol 1999, 125(11):589-597. (Pubitemid 29502339)
28. Nakachi K, Matsuyama S, Miyake S, Sugaruma M, Imai K: Preventive effects of drinking green tea on cancer and cardiovascular disease: epidemiological evidence for multiple targeting prevention. Biofactors 2000, 13(1-4):49-54. (Pubitemid 32107344)
29. Unno T, Takeo T: Absorption of (-)-epigallocatcechin gallate into the circulation system of rats. Biosci Biotechnol Biochem 1995, 59(8):1558-1559.
30. Zhu M, Chen Y, Li RC: Oral absorption and bioavailability of tea catechins. Planta Med 2000, 66(5):444-447. (Pubitemid 30413506)
31. Warden BA, Smith LA, Beecher GR, Balentine DA, Clevidence BA: Catechins are bioavailable in men and women drinking black tea throughout the day. J Nutr 2001, 131(6):1731-1737. (Pubitemid 32520439)
32. Nakagawa KMT: Absorption and distribution of tea catechin, (-)-epigallocatechin-3-gallate, in the rat. J Nutr Sci Vitaminol 1997, 43(6):679-684.
33. Yang CS: Inhibition of carcinogenesis by tea. Nature 1997, 389(6647):134-135.
34. Nakagawa K, Okuda S, Miyazawa T: Dose-dependent incorporation of tea catechins, (-)- epigallocatechin-3-gallate and (-)-epigallocatechin, into human plasma. Biosci Biotechnol Biochem 1997, 61(12):1981-1985. (Pubitemid 127473054)
35. van het Hof KH, Wiseman SA, Chang CS, Tijburg BM: Plasma and lipoprotein levels of tea catechins following repeated tea consumption. Proc Soc Exp Biol Med 1999, 220(4):203-209.
36. Yang CS, Chen L, Lee MJ, Balentine D, Kyo MC, Schantz SP: Blood and urine levels of tea catechins after ingestion of different amounts of green tea by human volunteers. Cancer Epidemiol Biomarkers Prev 1998, 7(4):351-354. (Pubitemid 28354149)
37. Chueh PJ, Wu L-Y, Morré DM, Morré DJ: TNOX is both necessary and sufficient as a cellular target for the anticancer actions of capsaicin and the green tea catechin (-)-epigallocatechin-3-gallate. Biofactors 2004, 20(4):235-249.
38. Cooper RD, Morré DJ, Morré DM: Medicinal benefits of green tea: Part II. Review of anticancer properties. J Altern Comp Med 2005, 11(4):639-652. (Pubitemid 41279080)
39. Isbrucker RA, Bausch J, Edwards JA, Wolz E: Safety studies on epigallocatechin gallate (EGCg) preparations. Part 1: genotoxicity. Food Chem Toxicol 2006, 44(5):626-635.
40. Isbrucker RA, Edwards JA, Wolz E, Davidovich A, Bausch J: Safety studies on epigallocatechin gallate (EGCg) preparations. Part 2: dermal, acute and short-term toxicity studies. Food Chem Toxicol 2006, 44(5):636-650.
41. Isbrucker RA, Edwards JA, Wolz E, Davidovich A, Bausch J: Safety studies on epigallocatechin gallate (EGCg) preparations. Part 3: Teratogenicity and reproductive toxicity studies in rats. Food Chem Toxicol 2006, 44(5):651-661.
42. National Center for Complementary and Alternative Medicine: Botanical Fact Sheet, Green Tea, Office of Dietary Supplements. Bethesda: National Institues of Health; 2012:2.
43. De Luca T, Morré DM, Morré DJ: Reciprocal relationship between cytosolic NADH and ENOX2 inhibition triggers sphingolipid-induced apoptosis in HeLa cells. J Cell Biochem 2010, 110(6):1504-1511.